Literature DB >> 16338936

QRS duration and late mortality in unselected post-infarction patients of the revascularization era.

Axel Bauer1, Mari A Watanabe, Petra Barthel, Raphael Schneider, Kurt Ulm, Georg Schmidt.   

Abstract

AIMS: To assess the association of prolonged QRS duration and late mortality in unselected post-infarction patients of the revascularization era. METHODS AND
RESULTS: A total of 1455 survivors of acute myocardial infarction (MI) in sinus rhythm and under 76 years of age were enrolled. Ninety eight percent of the patients received reperfusion/revascularization therapy (90% percutaneous coronary intervention). After revascularization, prolonged QRS duration (>or=120 ms) was present in 87 patients (6.0%). Additional risk factors studied were age (>or=65 years), presence of diabetes mellitus, history of previous MI, mean heart rate (>75 b.p.m.), heart rate variability index (<or=20 U), arrhythmia on Holter, left ventricular ejection fraction (LVEF<or=30%), and heart rate turbulence (HRT). Primary endpoint was total mortality. During a follow-up period of 22+/-5 months, 70 patients died. On multivariable analysis, prolonged QRS duration showed the highest association with total mortality (hazard ratio 4.0; CI 2.3-6.9) followed by HRT Category 2 (3.8; 2.0-7.3) and LVEF<or=30% (3.1; 1.7-5.6). The association of prolonged QRS duration and late mortality was particularly strong in patients with LVEF<or=30% (5.0; 1.8-14.1). On multivariable analysis of secondary endpoints, prolonged QRS duration was significantly associated with cardiac mortality (3.9; 1.9-7.8), but not with sudden death and serious arrhythmic events.
CONCLUSION: In the revascularization era, incidence of prolonged QRS duration is reduced. However, prolonged QRS duration is still highly correlated with increased late mortality.

Entities:  

Mesh:

Year:  2005        PMID: 16338936     DOI: 10.1093/eurheartj/ehi683

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  7 in total

Review 1.  The year of 2006 in electrocardiology.

Authors:  Shlomo Stern
Journal:  Ann Noninvasive Electrocardiol       Date:  2007-04       Impact factor: 1.468

2.  QRS and QTc interval prolongation in the prediction of long-term mortality of patients with acute destabilised heart failure.

Authors:  Tobias Breidthardt; Michael Christ; Miriam Matti; Delia Schrafl; Kirsten Laule; Markus Noveanu; Tujana Boldanova; Theresia Klima; Willibald Hochholzer; André P Perruchoud; Christian Mueller
Journal:  Heart       Date:  2007-03-29       Impact factor: 5.994

3.  Fragmented QRS in prediction of cardiac deaths and heart failure hospitalizations after myocardial infarction.

Authors:  Petri Korhonen; Terhi Husa; Teijo Konttila; Ilkka Tierala; Markku Mäkijärvi; Heikki Väänänen; Janne Ojanen; Aki Vehtari; Lauri Toivonen
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

Review 4.  Who should receive an implantable cardioverter-defibrillator after myocardial infarction?

Authors:  Stavros Mountantonakis; Mathew D Hutchinson
Journal:  Curr Heart Fail Rep       Date:  2009-12

5.  Clinical implications of QRS duration and QT peak prolongation in patients with suspected coronary disease referred for elective cardiac catheterization.

Authors:  M Nadeem Attar; Kenneth Wong; David G Groves; Nick Newall; David R Ramsdale; Roger K Moore
Journal:  Ann Noninvasive Electrocardiol       Date:  2008-04       Impact factor: 1.468

6.  Prognostic value of contrast-enhanced cardiac magnetic resonance imaging in patients with newly diagnosed non-ischemic cardiomyopathy: cohort study.

Authors:  Karin A L Müller; Iris Müller; Ulrich Kramer; Reinhard Kandolf; Meinrad Gawaz; Axel Bauer; Christine S Zuern
Journal:  PLoS One       Date:  2013-02-20       Impact factor: 3.240

7.  Heart rate turbulence as risk-predictor after myocardial infarction.

Authors:  Christine S Zuern; Petra Barthel; Axel Bauer
Journal:  Front Physiol       Date:  2011-12-12       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.